To acquire or not to acquire - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks


Login Failure
(Please do not use this option on a public machine)
  Sign Up | Forgot Password?  

To acquire or not to acquire

Jan 27, 2009

Pfizer's big gamble
'Acquisitions' seem to be on the agenda of the global pharma industry; especially big ticket ones. The world's largest drugmaker Pfizer is said to be in talks with Wyeth to acquire the latter at a deal size pegged to be worth more than US$ 60 bn. While there is no confirmation of the same as yet, the reasons why Pfizer would go in for it are manifold. It is now a well established fact that global pharma majors are finding it increasingly difficult to replenish their pipelines with new path breaking drugs while the R&D costs are mounting. As a result, many of them had already started looking to acquire either a portfolio of products or acquire smaller companies which had a few promising drugs in their pipelines but did not have the requisite funding. Biotech companies especially got classified in the latter category. But with the credit crisis now afflicting the global economy, many biotech companies seem to be shutting shop and are no longer a viable option.

Secondly, Pfizer's major drug, which is the largest drug in the world with global revenues of US$ 12 bn is set to lose its patent in 2011. And the company does not have another blockbuster to fill Lipitor's shoes. If the deal with Wyeth goes through, once the patent of Lipitor expires in 2011, Pfizer will suffer a 10% fall in earnings as compared to 23% (if it does not go through). Thirdly, Wyeth has some strong drugs in its pipeline such as Enbrel and the vaccine Prevnar, which are blockbusters. If the deal goes through, it will most likely trigger a wave of consolidation in the industry as rival companies also look to grow in size to compete. The real problem for Pfizer of course could be the funding of the deal. US$ 60 bn is by no means a small amount especially in an environment where credit has dried up and the recession has deepened. It would be interesting to see how Pfizer makes this feasible without loading its balance sheet with too much debt.

Forex woes continue
Forex losses have continued to afflict major Indian companies during the December ended quarter. With the volatile moves of the rupee baffling everybody, forex losses this quarter have only mounted. As reported in a leading business daily, around 30 companies so far have reported a combined forex loss of Rs 37 bn for this quarter. These losses are generally due to cancellation of forward contracts at unrenumerative rates and the revaluation of their foreign currency loans. While more than two thirds of the same are due to hedging practices, the remaining are due to revaluation of dollar liabilities. Not surprisingly, IT and pharma majors have borne the maximum brunt of forex losses given that these sectors are highly export oriented.

Those who have been relying on Foreign Currency Convertible Bonds (FCCBs) especially are paying a heavy price. A couple of years back when the stockmarkets were buoyant, FCCBs were being announced by the dozen, some with exorbitant premiums promised at the time of redemption. The reversal in the fortunes of the stockmarkets has put all these companies in a tight spot. Given the meltdown, conversion of these bonds into equity shares looks highly unlikely. Moreover, the spectre of redemption is hanging like a Damocles sword over these companies as funding the same has become an issue. And the sharp fall in the value of the rupee has only exacerbated forex losses on these loans thereby impacting profitability. Thus, those companies without adequate cash flows are in for some troubled times.

A dull lustre indeed
Looks like paint companies will have to brace themselves for a tough quarter. India's leading paint company Asian Paints reported an unenthusing set of numbers on Friday, wherein sales grew by a tepid 12% YoY and operating margins nearly halved. This is not surprisingly given that the growth of the paint industry is correlated to the GDP growth. With the growth of the latter having slowed down, the growth of the paint sector has been restricted as well. Mr. Ashwin Dani, the MD of Asian Paints said, "We could see demand conditions slowing down. We view these as short term challenges and we are hopeful that the situation will improve in the next financial year". We hope so too, but with 2009 also predicted to be a tough year for the global economy, it remains to be seen how Indian companies are able to cope with the same.

Equitymaster requests your view! Post a comment on "To acquire or not to acquire". Click here!


More Views on News

Can the Nifty Fall to 10,200? (Fast Profits Daily)

Sep 24, 2020

The Nifty has reached an important support level today. If it breaks then we could see further downside.

How to Save Money by Exiting Stocks Before They Fall podcast (Views On News)

Sep 24, 2020

A penny saved is a penny earned. It doesn't matter where you enter. All that matter is where you exit. Watch this video to identify an opportune time to exit your investments and book profits.

ICICI Prudential ESG Fund: Aims for Sustainability (Outside View)

Sep 24, 2020

PersonalFN briefly explains the newly launched fund : ICICI Prudential ESG Fund.

What to Do if there is a Second Wave of the Stock Market Crash (Profit Hunter)

Sep 24, 2020

Here's what I think investors should do in this selloff.

IDFC Mutual Fund Starts Campaign 'SIFI'. Should Buy Into the Idea? (Outside View)

Sep 23, 2020

IDFC Mutual Fund is taking the road less travelled and hence started a campaign SIFI (SIP in Fixed Income) to promote the concept of SIP for its debt funds investors.

More Views on News

Most Popular

Why We Picked This Small-cap Stock for Our Hidden Treasure Subscribers (Profit Hunter)

Sep 17, 2020

This leading household brand will profit big time in a post covid world.

My Top Stock to Buy in this Market Selloff (Profit Hunter)

Sep 22, 2020

The recent correction offers a great opportunity to buy this high conviction smallcap stock.

What Do the Charts Say About Buying Smallcaps Now? (Fast Profits Daily)

Sep 18, 2020

Everyone seems to be excited about buying smallcaps now...but is it the right thing to do? What do the charts tell us? Find out in this video...

How Much Money Do You Need to Be a Professional Trader? (Fast Profits Daily)

Sep 17, 2020

In this video I'll answer a question I get asked often: How much capital do I really need to trade the markets for a living? Let's find out...


Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms


Sep 25, 2020 09:13 AM